Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Postmarketing, Multicenter, Longitudinal, Prospective, Pharmacokinetic, Phase 1B Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

NCT04163016 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04163016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04163016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Postmarketing, Multicenter, Longitudinal, Prospective, Pharmacokinetic, Phase 1B Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
Lead sponsor
UCB Biopharma SRL
Phase
Phase 1
Overall status
Completed
Start date
June 19, 2020
Completion date
May 23, 2023
Enrollment
22 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

axial spondyloarthritis, crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis